Home

Martha Enger Lab

Main content

Professor Martha Chekenya Enger

Welcome to the Brain Tumor Immunology & Therapy lab

The group is led by Dr Martha Chekenya Enger and is one of five labs that form the larger Translational Cancer Research Group

Publications (PubMed)

BTi - Moving Basic Research Closer To the Clinic

hampered progress of clinical trials in oncology
covid-19_effect_on_the_clinical_trial_bortem-17

The effect of the COVID-19 pandemic on clinical brain cancer trials

2020 evolved into an annus horribilis for everyone, manifested by physical distancing and social isolation, disrupted work routines and for many, tragic loss of livelihood and loved ones.

Principal Investigator
Photo of Martha Chekenya Enger

Martha Chekenya Enger

Education: First-class Honours BSc Psychology from the University of Westminster, London, UK. Master of Science in Neuroscience from The Institute of Psychiatry/King's College, University of London. PhD at King's, Guy's, St Thomas' School of Medicine and Dentistry, University of...

Special Issue
Drawing of head and brain

Invitation to submit a research article to Cancers (IF 6.13)

"Immunological, Molecular and Imaging Biomarkers of Malignant Progression in Brain Cancer: Improving Precision Neuro-Oncology"

User involvement
Hjernesvulstforeningen besøker Brain tumor Immunology and Therapy Group hos Instituttet for biomedisin

Patient organization collaborates with researchers to improve brain cancer therapy

The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.

Research project
Logo Hjernesvulstforeningen

Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.